Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
MAP1LC3A Antibody, ATG8E Antibody, LC3 Antibody, LC3A Antibody, MAP1BLC3 Antibody, MAP1A/1B light chain 3 A Antibody, MAP1A/MAP1B LC3 A Antibody, MAP1A/MAP1B light chain 3 A Antibody, MAP1ALC3 Antibody
MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. The protein encoded by this gene is one of the light chain subunits and can associate with either MAP1A or MAP1B. Two transcript variants encoding different isoforms have been found for this gene.
Fluorescent image of U251 cells stained LC3 (APG8A) antibody.U251 cells were treated with Chloroquine (50 mu M,16h), then fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated LC3 (APG8A) primary antibody (1:200, 2 h at room temperature). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h). Nuclei were counterstained with Hoechst 33342 (blue) (10 ug/ml, 5 min). LC3 immunoreactivity is localized to autophagic vacuoles in the cytoplasm of U251 cells.
Western blot of LC3 (APG8a) (arrow) using purified antibody. 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the LC3 (APG8a) gene (Lane 2) (Origene Technologies).